Tranexamic Acid in Abdominoplasty.

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators prepared a novel tranexamic acid (TXA) study designed to estimate the quantity of blood loss in patients undergoing abdominoplasty surgery. This study aims to quantify blood loss during abdominoplasty with and without TXA. The central hypothesis is that TXA administration reduces blood loss and fibrinolysis in patients undergoing abdominoplasty surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Poznan University of Medical Sciences
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Scheduled abdominoplasty

• ASA 1 or 2

• age >18 and <75 years

Exclusion Criteria:

• BMI <20 or >35 kg/m2

• ASA 3 or > 3

• medical history of thromboembolism

• history of hematological disease

• treatment with aspirin 14 days before the procedure

• treatment with anticoagulants 5 days before the procedure

• epilepsy

• allergy to tranexamic acid

• coagulation disorders